Introduction to biological and small molecule drug research and development : theory and case studies / edited by Robin Ganellin, Stanley Roberts, Roy Jefferis.

Format:

Book

Contributor:

Ganellin, C. R. (C. Robin), editor of compilation.

Jefferis, Roy, editor of compilation.

Roberts, Stanley M., editor of compilation.

Series:

Gale eBooks

Language:

English

Subjects (All):

Drug development.

Biopharmaceutics.

Physical Description:

1 online resource (xx, 425 pages, 21 unnumbered pages of plates) : illustrations (some color)

Place of Publication:

Waltham, Mass. : Elsevier, 2013.

Oxford : Elsevier, 2013.

Language Note:

English

Summary:

Introduction to Biological and Small Molecule Drug Research and Development provides, for the first time, an introduction to the science behind successful pharmaceutical research and development programs. The book explains basic principles, then compares and contrasts approaches to both biopharmaceuticals (proteins) and small molecule drugs, presenting an overview of the business and management issues of these approaches. The latter part of the book provides carefully selected real-life case studies illustrating how the theory presented in the first part of the book is actually put i

Contents:

Front Cover; Introduction to Biological and Small Molecule Drug Research and Development: Theory and Case Studies; Copyright; Contents; Biographies; Preface; Chapter 1 - Introduction to enzymes, receptors and the action of small molecule drugs; 1.1 SECTION I: BACKGROUND INFORMATION; 1.2 SECTION II: MORE ABOUT ENZYMES; 1.3 SECTION III: MORE ABOUT RECEPTORS; 1.4 SECTION IV; Further Reading; Chapter 2 - Protein structure and function; 2.1 INTRODUCTION; 2.2 GENERAL ASPECTS OF PROTEIN STRUCTURE; 2.3 ENZYMES; 2.4 PROTEIN RECEPTORS; 2.5 STRUCTURAL PROTEINS AS DRUG TARGETS; 2.6 PROTEINS AS DRUGS

2.7 CONCLUDING REMARKSReferences; Chapter 3 - The small molecule drug discovery process - from target selection to candidate selection; 3.1 INTRODUCTION; 3.2 WHERE DO LEADS COME FROM?; 3.3 LEAD GENERATION: ACTIVE-TO-HIT; 3.4 LEAD GENERATION: HIT-TO-LEAD; 3.5 LO - ESTABLISHING THE SCREENING CASCADE AND CANDIDATE BIOLOGICAL TARGET PROFILE; References and Notes; Further Reading; Chapter 4 - Protein therapeutics (introduction to biopharmaceuticals); 4.1 INTRODUCTION; 4.2 TYPES OF PROTEIN THERAPEUTICS I: REGULATORY AND ENZYMATIC ACTIVITY; 4.3 TYPES OF PROTEIN THERAPEUTICS II: TARGETING ACTIVITY

4.4 CHALLENGES OF PROTEIN THERAPEUTICS4.5 FUTURE DIRECTIONS FOR PROTEIN THERAPEUTICS; 4.6 BIOSIMILAR PROTEIN THERAPEUTICS; 4.7 SUMMARY AND CONCLUSIONS; References; Further Reading; Chapter 5 - Similarities and differences in the discovery and use of biopharmaceuticals and small-molecule chemotherapeutics; 5.1 INTRODUCTION; 5.2 HOW DO SMDS DIFFER FROM BIOMOLECULAR DRUGS?; 5.3 HISTORICAL CHANGES TO THE FDA APPROACH TO HANDLE THE BIOTECH BOOM-THE DIFFERING NOMENCLATURE FOR SMALL MOLECULES VS BIOLOGI ...; 5.4 COMPARISONS OF CLINICAL METRICS-BIOLOGICS VS SMALL MOLECULES

5.5 ARE PEPTIDE DRUGS SMALL MOLECULES OR BIOLOGICS?5.6 THE MANUFACTURE AND SUPPLY OF SMDS VS BIOMOLECULAR DRUGS; 5.7 THE PRICING OF SMDS VS BIOMOLECULAR DRUGS; 5.8 COMPARING SMALL-MOLECULE, PEPTIDE AND BIOMOLECULAR DRUGS IN THE MARKET; 5.9 BIOSIMILAR BIOMOLECULES VS GENERIC SMALL MOLECULES; 5.10 DISCOVERY AND PRECLINICAL STAGES FOR SMDS VS BIOMOLECULAR DRUGS-WHERE THE TECHNOLOGIES DIFFER THE MOST; 5.11 SMALL-MOLECULE AND BIOLOGICS APPROVALS BY THERAPY AREAS; 5.12 MANAGING SMALL-MOLECULE & BIOMOLECULAR DRUG R&D IN THE SAME COMPANY; 5.13 CONCLUSION; References

Chapter 6 - Therapies for type 2 diabetes: modulating the incretin pathway using small molecule peptidase inhibitors or pep ...6.1 INTRODUCTION; 6.2 PHARMACOTHERAPY OF TYPE 2 DIABETES; 6.3 THE RATIONALE FOR INCRETIN-BASED THERAPIES FOR TYPE 2 DIABETES; 6.4 DISCOVERY AND PHARMACOKINETICS OF THE INCRETIN-BASED THERAPIES; 6.5 CLINICAL EFFICACY OF THE INCRETIN-BASED THERAPIES; 6.6 EVIDENCE FOR DISEASE MODIFICATION; 6.7 IMPACT ON CARDIOVASCULAR RISK; 6.8 CLINICAL SAFETY AND TOLERABILITY OF INCRETIN-BASED THERAPIES; 6.9 CONCLUSIONS; References

Chapter 7 - The structure and business of biopharmaceutical companies including the management of risks and resources

Notes:

Description based upon print version of record.

Includes bibliographical references and index.

ISBN:

9780123977700

0123977703

OCLC:

849927687